Tag Archives: vandetanib
FDA Panel Supports the Use of Vandetanib in Medullary Thyroid Cancer
An FDA advisory committee reported that they supported the use of AstraZeneca’s vandetanib for the treatment of patients with medullary thyroid cancer (MTC). However, they also indicated the drug should be reserved for patients who are experiencing symptoms of their … Continue reading
Posted in Cancer, Thyroid Cancer
Tagged disease progression, Medullary Thyroid Cancer, vandetanib
Comments Off on FDA Panel Supports the Use of Vandetanib in Medullary Thyroid Cancer